This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Progenics, Wyeth Bowel Drug Fails Phase III Study

Updated from 9:14 a.m. EDT

Progenics (PGNX) and Wyeth (WYE) said Wednesday that their experimental bowel drug, intravenous methylnaltrexone, failed a phase III study in patients undergoing surgery.

The negative results are a significant setback for the drug, also known as MNTX, as the companies face competition from another, similar bowel drug being developed by Adolor (ADLR) and GlaxoSmithKline (GSK).

Progenics shares closed Tuesday at $13.55. The stock was tumbling 57% to $5.76 in morning trading Wednesday.

The failed phase III study investigated the use of MNTX as a treatment for post-operative ileus, a medical term for painful bloating and constipation following abdominal surgery.

Progenics and Wyeth said MNTX, administered intravenously, did not reduce the time required for gastrointestinal function to return to normal, compared to a placebo. The drug also failed to help patients leave the hospital sooner.

The companies are conducting a second phase III study with a similar design. Results are expected in the middle of the year.

There are no drugs currently approved to treat POI. That, however, may change in May, when the Food and Drug Administration is expected to issue a decision on Entereg, a bowel drug administered as a pill that is being developed by Adolor and GlaxoSmithKline.

In early February, the FDA pushed back the decision date on Entereg to take more time to review the drug's data, including a risk-management plan submitted by the companies to better inform doctors and patients of safety risks.

(Full disclosure, I had been bullish on Progenics since the stock was $18 and bearish on Adolor because I thought MNTX was a superior drug. Clearly, Wednesday's negative study results from MNTX is a big knock to that call.)

MNTX is a variation of naltrexone, a drug approved and used today to treat opioid and alcohol dependence.

MNTX has been filed with the FDA for the treatment of patients with advanced medical illness. These are nursing home and hospice patients in the advanced stages of disease who require heavy doses of painkillers.

An FDA approval decision was expected in February, but was pushed back until April so the agency could review more safety data.

Know What You Own: Progenics operates in the pharmaceutical sector of the healthcare industry, and some of the other stocks in its field include Eli Lilly (LLY), Novartis (NVS) and Pfizer (PFE). These stocks were recently trading at $50.23, $48.07 and $21.46, respectively.

Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs